PSMA PET-directed surgical metastasis-directed therapy in metachronous prostate cancer

We present the case of a patient who underwent an open radical prostatectomy with pelvic lymph node dissection (Gleason 4+3, pT3a pN1 R0) in March 2017. In November 2020, prostate-specific membrane antigen (PSMA)-radioguided salvage lymph node dissection was planned due to a single left para-rectal...

Descripción completa

Detalles Bibliográficos
Autores principales: Ambrosini, Francesca, Koehler, Daniel, Ghadban, Tarik, Jacobsen, Frank, Knipper, Sophie, von Amsberg, Gunhild, Steuber, Thomas, Maurer, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Polish Urological Association 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690390/
https://www.ncbi.nlm.nih.gov/pubmed/38045775
http://dx.doi.org/10.5173/ceju.2023.69
Descripción
Sumario:We present the case of a patient who underwent an open radical prostatectomy with pelvic lymph node dissection (Gleason 4+3, pT3a pN1 R0) in March 2017. In November 2020, prostate-specific membrane antigen (PSMA)-radioguided salvage lymph node dissection was planned due to a single left para-rectal lymph node at a [(68)Ga] Ga-PSMA-I&T PET. In January 2022, the [(68)Ga] Ga-PSMA-I&T PET showed an isolated liver lesion. Biopsy confirmed prostate adenocarcinoma. A liver segmentectomy was performed. A complete biochemical response was reported until the last follow-up (December 2022). Prostate-specific membrane antigen positron emission tomography (PSMA PET)-directed metastasis-directed therapy may be an effective treatment in selected cases, allowing a benefit in the oncological outcome.

Ejemplares similares